Minimal Residual Disease Negativity Does Not Overcome Poor

  • Slides: 12
Download presentation
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study Chutima Kunacheewa, Hans C. Lee, Krina Patel, Sheeba Thomas, Behrang Amini, Samer Srour, Qaiser Bashir, Yago Nieto, Muzzaffar H. Qazilbash, Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch Clinical Lymphoma, Myeloma and Leukemia Volume 20 Issue 5 Pages e 221 -e 238 (May 2020) DOI: 10. 1016/j. clml. 2020. 01. 001 Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI:

Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 1 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 2 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 3 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 4 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 4 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 5 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 5 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 6 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 6 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 7 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 7 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Supplemental Figure 8 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238

Supplemental Figure 8 Clinical Lymphoma, Myeloma and Leukemia 2020 20 e 221 -e 238 DOI: (10. 1016/j. clml. 2020. 01. 001) Copyright © 2020 Elsevier Inc. Terms and Conditions

Residual Income Valuation What is residual income ResidualResidual Income Valuation What is residual income Residual
Residual Income Valuation What is residual income ResidualResidual Income Valuation What is residual income Residual
residual stresses residual stresses analysis of residual stressesresidual stresses residual stresses analysis of residual stresses
Peripheral Immunotype Correlates with Minimal Residual Disease StatusPeripheral Immunotype Correlates with Minimal Residual Disease Status
Minimal Residual Disease Testing Dr Christopher Venner CrossMinimal Residual Disease Testing Dr Christopher Venner Cross
Minimal Residual Disease and Biomarkers ASH 2015 SummaryMinimal Residual Disease and Biomarkers ASH 2015 Summary
Minimal Residual Disease bepaling bij CLL Waarom zouMinimal Residual Disease bepaling bij CLL Waarom zou
The role of Minimal Residual Disease in theThe role of Minimal Residual Disease in the
Detection of minimal residual disease following induction immunochemotherapyDetection of minimal residual disease following induction immunochemotherapy
Value of Minimal Residual Disease MRD Negative StatusValue of Minimal Residual Disease MRD Negative Status
Minimal Residual Disease MRD Testing in Newly DiagnosedMinimal Residual Disease MRD Testing in Newly Diagnosed